
NVIDIA BioNeMo Platform Powers AI Drug Discovery Across Pharma and Biotech Industry
NVIDIA's BioNeMo platform is being adopted by pharmaceutical giants and biotech startups to build AI foundation models for drug discovery and biological research. The platform enables companies like Eli Lilly, Thermo Fisher, and multiple AI-native biotech firms to develop autonomous research infrastructure. This deployment positions AI as core infrastructure for biotechnology rather than an experimental tool.



















